Recombinant Human Cholecystokinin receptor type A (CCKAR)

What is the structural classification of CCKAR and what are its key structural domains?

CCKAR belongs to the G-protein-coupled receptor (GPCR) superfamily, specifically the β-branch of the rhodopsin family. The receptor consists of seven transmembrane segments with distinct functional domains including cholesterol recognition/interaction amino acid consensus (CRAC) motifs and cholesterol consensus motif (CCM) sequence motifs. Key structural features include the conserved "micro-switches" (PIF, ERY, CWxP, and NPxxY) that are typical of active GPCRs. These structural elements undergo significant conformational changes during activation, including an approximately 9-Å outward movement of TM6 and a 4-Å inward shift of TM7 compared to inactive states . The carboxyl terminus of CCKAR contains multiple serine and threonine residues that play critical roles in receptor internalization and signaling regulation .

What is the mechanism of ligand recognition by CCKAR?

CCKAR recognizes its endogenous ligand cholecystokinin, particularly the sulfated octapeptide form (CCK-8). Structural studies have revealed that CCK-8 binding involves specific interactions with residues in the transmembrane helices and extracellular domains of CCKAR. The sulfation of CCK-8 is particularly important for high-affinity binding. When CCK-8 binds to CCKAR, it stabilizes the active conformation of the receptor, which then allows for G-protein coupling and subsequent signal transduction. Specific binding pockets within transmembrane segments, particularly TM3, play critical roles in agonist recognition . The ligand binding triggers conformational changes that propagate through the receptor structure to affect the orientation of intracellular domains, particularly the movement of TM6 away from the receptor core .

What are the optimal expression systems for recombinant human CCKAR production?

Chinese hamster ovary (CHO) cells have been established as an effective expression system for recombinant human CCKAR. These cells can be transfected using lipid-based methods such as Lipofectamine LTX with vectors containing the CCKAR cDNA and a selection marker like the neomycin resistance gene . When properly optimized, this system can provide up to 25-fold higher receptor density compared to native pancreatic acinar cells, making it ideal for structural and functional studies .

For successful expression, researchers should:

• Use expression vectors with strong promoters (like SRa)

• Optimize transfection conditions specifically for CCKAR

• Establish stable cell lines through antibiotic selection

• Verify receptor expression through radioligand binding assays

• Select cell clones with appropriate receptor densities (typically in the range of 60-300 × 10³ receptors/cell)

How can researchers verify proper expression and folding of recombinant CCKAR?

Verification of proper CCKAR expression and folding requires multiple complementary approaches:

• Radioligand binding assays: Using 125I-BH-CCK-8 to determine receptor density and binding affinity. Properly folded receptors should demonstrate specific high-affinity binding with IC50 values between 0.3-0.7 nM for CCK-8 .

• Functional assays: Calcium mobilization assays using calcium-sensitive dyes like Fura Red/AM can verify signal transduction capacity. Properly folded receptors should respond to ligand stimulation with appropriate calcium flux .

• Biochemical characterization: Affinity labeling followed by SDS-PAGE analysis can identify receptor proteins. Deglycosylation experiments using endoglycosidase F can confirm core protein sizes .

• Confocal microscopy: Using fluorescently-labeled ligands (like RG-CCK-8) to visualize receptor localization and internalization .

• Sensitivity to GTP analogs: Functional recombinant CCKAR should demonstrate appropriate sensitivity to stable GTP analogs, similar to native receptors .

How do glycosylation patterns differ between native and recombinant CCKAR, and how does this affect functional studies?

Native and recombinant CCKAR show notable differences in glycosylation patterns despite having the same core protein size. Biochemical characterization has revealed that while both native and recombinant forms represent complex glycoproteins, only the native receptor binds to Ulex europeus agglutinin I, a lectin that recognizes fucose residues added during late glycoprotein biosynthesis . This suggests differences in terminal glycosylation steps between expression systems.

Despite these structural differences in glycosylation, functional studies demonstrate that recombinant CCKAR in CHO cells is functionally indistinguishable from native pancreatic acinar cell receptors. This functional equivalence includes:

• Similar ability to initiate signaling cascades

• Comparable sensitivity to stable GTP analogues

• Equivalent binding affinities for both agonists and antagonists

These findings indicate that while glycosylation differences may affect electrophoretic mobility (with recombinant CCKAR migrating faster on SDS-PAGE than the native M(r) 85,000-95,000 molecule), they do not significantly impact the receptor's pharmacological properties. This makes recombinant systems valid models for studying CCKAR function despite glycosylation differences .

What are the recommended methodologies for studying CCKAR internalization?

Studying CCKAR internalization requires specialized techniques to track receptor trafficking following ligand binding. Based on established protocols, the following methodologies are recommended:

• Acid wash/radioligand stripping assays: Cells expressing CCKAR are incubated with radiolabeled ligand (e.g., 125I-BH-CCK-8) for various time periods. Surface-bound ligand is then stripped using an acidic buffer (pH 2.0-3.0), allowing quantification of internalized vs. surface-bound ligand .

• Confocal microscopy visualization: This approach provides direct visualization of internalization dynamics. Cells are incubated with fluorescently-labeled CCK (e.g., rhodamine green-labeled CCK-8) while cell membranes are counterstained with rhodamine B-labeled concanavalin A. Overlaid images can distinguish surface-localized from internalized receptors:

  • Yellow coloration indicates surface colocalization

  • Green intracellular fluorescence indicates internalized receptor-ligand complexes

• Flow cytometry: This method can be used to quantify receptor surface expression before and after ligand exposure .

• Mutation studies: To investigate the molecular determinants of internalization, researchers can generate truncation mutants (e.g., CCKAR Tr399) or serine/threonine-to-alanine mutants (e.g., CCKAR ΔS/T) to assess the role of specific residues in the carboxyl terminus .

When designing internalization studies, it's important to include appropriate time courses (typically 5-60 minutes) and controls (such as temperature controls, since internalization is temperature-dependent) .

What techniques are most effective for measuring CCKAR-mediated signaling pathways?

Several complementary techniques can effectively measure CCKAR-mediated signaling:

• Calcium mobilization assays: Cells loaded with calcium-sensitive dyes (e.g., Fura Red/AM at 4 μg/ml) can detect intracellular calcium flux upon receptor activation. This requires:

  • Incubation with dye for 45 minutes at 37°C in calcium-containing buffer

  • Rest period of 30 minutes at room temperature

  • Real-time measurement using flow cytometry or plate readers

  • Baseline measurement followed by agonist addition

• Phosphorylation assays: Western blotting to detect phosphorylation of downstream effectors like ERK1/2, PKC, or other kinases activated by Gq, Gs, or Gi coupling.

• cAMP assays: For measuring Gs (stimulatory) or Gi (inhibitory) coupling effects on adenylyl cyclase activity.

• Reporter gene assays: Constructs containing response elements for transcription factors activated by CCKAR signaling can provide longer-term readouts of receptor activity.

• GTPγS binding assays: To measure direct G-protein activation by the receptor.

Experimental design should account for CCKAR's promiscuous G-protein coupling ability (Gs, Gi, and Gq) , as different cell types may show different predominant coupling patterns. Additionally, membrane cholesterol content significantly affects CCKAR signaling and should be controlled or measured in experimental setups .

How can researchers effectively modify CCKAR expression levels for functional studies?

Researchers can employ several strategies to modulate CCKAR expression levels:

• Stable transfection: For long-term studies, establishing stable cell lines with varying receptor densities through antibiotic selection pressure. Cell clones can be selected based on receptor density determined by radioligand binding (typical ranges: 26-291 × 10³ receptors/cell) .

• Inducible expression systems: Tetracycline-regulated or similar inducible promoter systems allow for controlled, titratable receptor expression.

• Inflammatory stimulation: In cells that naturally express CCKAR (such as immune cells), stimulation with pathogen-associated molecular patterns like lipopolysaccharide (LPS) can upregulate CCKAR expression. For example, overnight stimulation with LPS (1 μg/ml) has been shown to increase CCKAR expression in peripheral blood mononuclear cells .

• siRNA or shRNA knockdown: For reducing expression in cells with endogenous CCKAR.

• CRISPR/Cas9 gene editing: For complete knockout or precise modification of the CCKAR gene.

When modifying expression levels, it's critical to verify:

• Actual receptor density using binding assays

• Maintained binding affinity for ligands (IC50 should remain in the 0.3-0.7 nM range for CCK-8)

• Proper subcellular localization

• Normal signaling capacity relative to expression level

How does the Y140A mutation affect CCKAR function and what are its research applications?

The Y140A mutation in CCKAR, located within a cholesterol-binding motif and the conserved (E/D)RY signature sequence, creates a unique tool for studying receptor function in different cholesterol environments. This mutation produces a receptor phenotype that mimics wild-type CCKAR in a high cholesterol environment regardless of the actual membrane cholesterol content .

Key characteristics of the Y140A mutant include:

• Ligand binding and activity profiles similar to wild-type CCKAR in high cholesterol

• Altered sensitivity to various ligand chemistries

• Modified internalization patterns

• Changed sensitivity to GTP analogs

• Distinct anisotropy patterns with fluorescent CCK analogs

Research applications of this mutant include:

• Serving as a stable and cost-effective alternative to model systems that physically enhance membrane cholesterol

• Providing a screening platform for identifying positive allosteric modulators that might correct conformational changes induced by high cholesterol environments

• Investigating receptor-G protein coupling defects in metabolic syndrome

• Structure-function studies relating to cholesterol sensitivity

• Understanding how TM3 residues contribute to allosteric ligand binding

The Y140A mutation appears to pull the agonist trigger away from its Leu356 target on TM7, creating a distinct conformation of the intramembranous pocket that offers opportunities for pharmacological intervention .

What structural determinants control G-protein coupling selectivity in CCKAR?

CCKAR demonstrates promiscuous G-protein coupling ability, interacting with Gs, Gi, and Gq heterotrimers. Cryo-EM structural studies have provided insights into the structural determinants controlling this selectivity:

How do membrane cholesterol levels impact CCKAR structure and function?

Membrane cholesterol levels significantly impact CCKAR structure and function through specific interactions with cholesterol-binding domains. The effects include:

• Altered ligand binding: High cholesterol environments negatively affect CCK binding affinity and kinetics.

• Modified G-protein coupling: High cholesterol creates a receptor-G protein coupling defect, potentially contributing to altered signaling in metabolic syndrome.

• Structural changes: Cholesterol interacts with specific receptor domains, particularly those encoded by the third exon including most of transmembrane segments three and four.

• Cholesterol-binding motifs: CCKAR contains both "cholesterol recognition/interaction amino acid consensus" (CRAC) and "cholesterol consensus motif" (CCM) sequence motifs. Key residues include Tyr140 (Y3.51) in TM3 and Tyr237 (Y5.66) in an additional CRAC motif in TM5 .

• Mutational effects: Mutation of these key tyrosine residues to alanines negatively affects CCK binding and signaling. Notably, the Y140A mutation uniquely eliminates cholesterol sensitivity of CCKAR .

These findings suggest that cholesterol directly modulates CCKAR conformation through specific binding interactions rather than through general membrane effects. This has important implications for understanding CCKAR function in conditions with altered cholesterol metabolism, such as metabolic syndrome. The Y140A mutant provides a valuable tool for studying these effects by mimicking the high-cholesterol receptor conformation in normal cholesterol environments .

What is the role of CCKAR in immune cells and its potential immunomodulatory functions?

CCKAR expression has been identified in various immune cells and tissues, suggesting important immunomodulatory functions beyond its classical roles in the gastrointestinal system. Research has demonstrated:

• Expression pattern: CCKAR protein has been detected in peripheral blood mononuclear cells (PBMC) including monocytes, and CCKAR gene expression has been found in primary lymphoid organs (thymus, bursa) and secondary lymphoid tissues (spleen) .

• Regulation by inflammatory stimuli: CCKAR expression in immune cells can be modulated by pathogen-derived inflammatory stimuli such as lipopolysaccharide (LPS), suggesting a role in immune responses .

• Calcium signaling: Functional CCKAR in immune cells couples to calcium mobilization pathways, as demonstrated by loading cells with calcium-sensitive dyes like Fura Red/AM and measuring responses to receptor crosslinking .

• Immunological functions: In mammals, CCK/CCKAR interactions affect multiple immunological parameters including:

  • Regulation of lymphocyte functions

  • Modulation of monocyte activities

  • Potential influence on inflammatory responses

• Connection to appetite regulation: The immunomodulatory functions of CCKAR provide a potential mechanistic link between infection, inflammation, and altered food intake/growth during immune challenges .

These findings suggest that CCKAR may serve as an important communication node between the nervous, endocrine, and immune systems, potentially coordinating metabolic and immune responses during physiological and pathological conditions .

What are the key considerations for developing drugs targeting CCKAR for obesity treatment?

• Efficacy and safety concerns: Despite multiple candidates entering clinical trials, none has been approved so far due to limited efficacy and safety issues .

• Structural understanding: Precise structural information about ligand recognition and receptor activation is essential for rational drug design. Recent cryo-EM structures of CCK-8–CCK AR–G protein complexes provide important insights into these mechanisms .

• G-protein signaling selectivity: CCKAR couples with multiple G-protein subtypes (Gs, Gi, Gq). Understanding which signaling pathway is most relevant for appetite suppression versus side effects is crucial for developing biased ligands with improved therapeutic profiles .

• Cholesterol sensitivity: CCKAR function is significantly affected by membrane cholesterol levels, which are often elevated in obesity and metabolic syndrome. Drugs may need to correct the conformational changes induced by high cholesterol environments .

• Positive allosteric modulators: Development of intrinsically inactive positive allosteric modulators represents an attractive approach to minimize side effects while enhancing endogenous CCK signaling .

• Screening tools: The Y140A mutant of CCKAR provides a valuable tool for screening compounds that might correct the coupling defect observed in high cholesterol environments, potentially leading to more effective therapeutics for metabolic syndrome .

Understanding these considerations through advanced structural and functional studies of CCKAR will be essential for developing more effective and safer anti-obesity medications targeting this receptor .

How do carboxyl terminus modifications affect CCKAR internalization and signaling dynamics?

The carboxyl terminus of CCKAR plays a critical role in regulating receptor internalization and signaling dynamics. Experimental modifications of this domain have revealed:

• Truncation effects: Studies with truncated CCKAR (CCKAR Tr399) have demonstrated that despite significant shortening of the C-terminus, the receptor maintains normal internalization capabilities. This suggests that the minimal sequences necessary for internalization are preserved in this truncated form .

• Serine/threonine phosphorylation sites: The C-terminus contains multiple serine and threonine residues that serve as potential phosphorylation sites by G protein-coupled receptor kinases (GRKs) and other kinases. Mutation of all these residues to alanines (CCKAR ΔS/T) does not prevent receptor internalization, suggesting phosphorylation-independent mechanisms may be involved .

• Receptor binding properties: Despite these modifications, both truncated and serine/threonine-mutated receptors maintain similar binding affinities for CCK-8 (IC50s between 0.37 ± 0.11 and 0.7 ± 0.02 nM), comparable to wild-type receptors .

• Visualization of internalization: Confocal microscopy studies using fluorescent ligands show that both wild-type CCKAR and the modified versions (CCKAR Tr399 and CCKAR ΔS/T) effectively internalize ligand within 15 minutes, moving it from the cell surface to the interior of the cell .

These findings contradict the common paradigm for GPCR internalization, which often depends on C-terminal phosphorylation. CCKAR appears to utilize alternative mechanisms for internalization, which has implications for understanding its signaling regulation, desensitization processes, and potential for therapeutic targeting .